Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.52 |
| ▸ | CA2 | P00918 | 12/20 | 0.52 |
| ▸ | CA9 | Q16790 | 12/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 12/20 | 0.52 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD5 | P21918 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16627015 | 0.88 | CA1 (0.54) | CA1CA2CA9CA14TAS2R14 | |
| SCHEMBL16627013 | 0.88 | CA1 (0.54) | CA1CA2CA9CA14TAS2R14 | |
| SCHEMBL16627026 | 0.85 | DRD1 (0.53) | CA1CA2CA9CA14TAS2R14 | |
| SCHEMBL16627024 | 0.85 | DRD1 (0.53) | CA1CA2CA9CA14TAS2R14 | |
| SCHEMBL16625814 | 0.85 | ALDH1A1 (0.39) | CA1CA2CA9CA14CA7 | |
| SCHEMBL16627027 | 0.84 | DRD1 (0.52) | CA1CA2CA9CA14TAS2R14 | |
| SCHEMBL16627065 | 0.84 | CA1 (0.53) | CA1CA2CA9CA14TAS2R14 | |
| SCHEMBL17346497 | 0.83 | CA1 (0.58) | CA1CA2CA9CA14CA7 | |
| SCHEMBL18626359 | 0.78 | CA1 (0.52) | CA1CA2CA9CA14TAS2R14 | |
| SCHEMBL18626360 | 0.76 | CA1 (0.58) | CA1CA2CA9CA14CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181237-B2 | Substituted berbines and their synthesis | MALLINCKRODT LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | SUCAMPO PHARMA AMERICAS LLC | 2015-04-09 | — | — | US | disclosed |
| WO-2015051106-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | MALLINCKRODT LLC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | TYMS, NME2, TYMP | CA1 4211/4885CA2 4477/4885CA9 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.